Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Early results from a study funded by the National Institutes of Health (NIH) have shown that men with hormone-sensitive metastatic prostate cancer who have received a combination of the chemotherapy drug docetaxel and hormone therapy lived longer than patients who received hormone therapy alone.
The study enrolled 790 men with metastatic prostate cancer who received a form of hormone therapy known as ADT (androgen deprivation therapy). ADT reduces the levels of male hormones called androgens, which can stimulate prostate cancer cells. In addition to the hormone therapy, some men received docetaxel. Sixty-nine percent of men who received the combo chemo and hormone therapy were alive at three years compared with 52.5 percent of men who received hormone therapy alone.
Johns Hopkins Kimmel Cancer Center expert, Michael Carducci, M.D., is the Genitourinary Cancers Chair for the ECOG-ACRIN who, in collaboration with SWOG, Alliance for Clinical Trials in Oncology and NRG Oncology designed and conducted the trial known as E3805.
Further follow-up will be performed on patients with less extensive metastatic disease who participated in E3805 in order to define the effect of this treatment combination on these patients.